新药审批歌礼制药 ASC301月5日,歌礼宣布,近期已获得美国FDA对其口服小分子GLP-1,ASC30,在糖尿病受试者中的II期研究的新药临床试验(IND)的批准。百济神州 索托克拉片1月6日,百济神州宣布,其自研的1类新药新型BCL2抑制剂百悦达®(索托克拉片)获得国家药品监督管理局(NMPA)附条件批准,用于治疗既往接受过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的慢性...
Source Link新药审批歌礼制药 ASC301月5日,歌礼宣布,近期已获得美国FDA对其口服小分子GLP-1,ASC30,在糖尿病受试者中的II期研究的新药临床试验(IND)的批准。百济神州 索托克拉片1月6日,百济神州宣布,其自研的1类新药新型BCL2抑制剂百悦达®(索托克拉片)获得国家药品监督管理局(NMPA)附条件批准,用于治疗既往接受过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的慢性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.